Synaptic changes in Alzheimer's disease and its models

Neuroscience

Volumn 251, Issue , 2013, Pages 51-65

  Pozueta, J ^a   Lefort, R ^a   Shelanski, M L ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; Dendritic spines; Learning and memory; Mouse model; Synapse

Indexed keywords

ACTIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; ROLIPRAM;

ACTIN FILAMENT; ALZHEIMER DISEASE; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BRAIN ELECTROPHYSIOLOGY; CELL STRUCTURE; DENDRITIC SPINE; DISEASE MODEL; EXPERIMENTAL MOUSE; HUMAN; LONG TERM POTENTIATION; MEMORY DISORDER; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SYNAPSE;

(11)C-LABELED PITTSBURG COMPOUND B; AD; ADDL; ALZHEIMER'S DISEASE; AMYLOID PRECURSOR PROTEIN; APP; AΒ-DERIVED DIFFUSIBLE LIGAND; BETA-AMYLOID; CAMP RESPONSE ELEMENT BINDING PROTEIN; CELLULAR PRION PROTEIN; CREB; DENDRITIC SPINES; EARLY-ONSET FAMILIAL AD; EOFAD; FRIZZLED; FZ; GAP; GEF; GTPASE ACTIVATING PROTEINS; GUANINE NUCLEOTIDE EXCHANGE FACTOR; LEARNING AND MEMORY; LONG-TERM DEPRESSION; LONG-TERM POTENTIATION; LTD; LTP; MAMMALIAN TARGET OF RAPAMYCIN; MOUSE MODEL; MTOR; MTOR COMPLEX 2; MTORC2; N-METHYL-D-ASPARTATE; NEUROFIBRILLARY TANGLE; NEURON-SPECIFIC PROMOTER; NFT; NMDA; NMDAR; P21-ACTIVATED KINASE; PAK; PDAPP; PIB; PRPC; SENILE PLAQUE; SP; SYNAPSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DENDRITIC SPINES; DISEASE MODELS, ANIMAL; MICE; NEURONAL PLASTICITY; SYNAPSES;

EID: 84884285081     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.05.050     Document Type: Review

References (199)

1. Abbott, Howlett, Francis, Williams Abeta(1-42) modulation of Akt phosphorylation via alpha7 nAChR and NMDA receptors. Neurobiol Aging 2007.
2. Allen B., Ingram E., Takao M., Smith M.J., Jakes R., Virdee K., Yoshida H., Holzer M., Craxton M., Emson P.C., Atzori C., Migheli A., Crowther R.A., Ghetti B., Spillantini M.G., Goedert M. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 2002, 22:9340-9351.
3. Alpar A., Ueberham U., Bruckner M.K., Seeger G., Arendt T., Gartner U. Different dendrite and dendritic spine alterations in basal and apical arbors in mutant human amyloid precursor protein transgenic mice. Brain Res 2006, 1099:189-198.
4. An W.-L., Cowburn R.F., Li L., Braak H., Alafuzoff I., Iqbal K., Iqbal I.-G., Winblad B., Pei J.-J. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol 2003, 163:591-607.
5. Andorfer C., Kress Y., Espinoza M., de Silva R., Tucker K.L., Barde Y.A., Duff K., Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 2003, 86:582-590.
6. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42:631-639.
7. Baki L., Shioi J., Wen P., Shao Z., Schwarzman A., Gama-Sosa M., Neve R., Robakis N.K. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J 2004, 23:2586-2596.
8. Bastrikova N., Gardner G.A., Reece J.M., Jeromin A., Dudek S.M. Synapse elimination accompanies functional plasticity in hippocampal neurons. Proc Natl Acad Sci U S A 2008, 105:3123-3127.
9. Becker J.A., Hedden T., Carmasin J., Maye J., Rentz D.M., Putcha D., Fischl B., Greve D.N., Marshall G.A., Salloway S., Marks D., Buckner R.L., Sperling R.A., Johnson K.A. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol 2011, 69:1032-1042.
10. Bekinschtein P., Katche C., Slipczuk L.N., Igaz L.M., Cammarota M., Izquierdo I., Medina J.H. mTOR signaling in the hippocampus is necessary for memory formation. Neurobiol Learn Mem 2007, 87:303-307.
11. Benard V., Bohl B.P., Bokoch G.M. Characterization of rac and cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases. J Biol Chem 1999, 274:13198-13204.
12. Bierer L.M., Hof P.R., Purohit D.P., Carlin L., Schmeidler J., Davis K.L., Perl D.P. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol 1995, 52:81-88.
13. Biscaro B., Lindvall O., Hock C., Ekdahl C.T., Nitsch R.M. Abeta immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice. J Neurosci 2009, 29:14108-14119.
14. Blessed G., Tomlinson B.E., Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968, 114:797-811.
15. Boekhoorn K., Terwel D., Biemans B., Borghgraef P., Wiegert O., Ramakers G.J., de Vos K., Krugers H., Tomiyama T., Mori H., Joels M., van Leuven F., Lucassen P.J. Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy. J Neurosci 2006, 26:3514-3523.
16. Borchelt D.R., Ratovitski T., van Lare J., Lee M.K., Gonzales V., Jenkins N.A., Copeland N.G., Price D.L., Sisodia S.S. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19:939-945.
17. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., Slunt H.H., Wang R., Seeger M., Levey A.I., Gandy S.E., Copeland N.G., Jenkins N.A., Price D.L., Younkin S.G., Sisodia S.S. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996, 17:1005-1013.
18. Brion J.P., Tremp G., Octave J.N. Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. Am J Pathol 1999, 154:255-270.
19. Buttini M., Masliah E., Barbour R., Grajeda H., Motter R., Johnson-Wood K., Khan K., Seubert P., Freedman S., Schenk D., Games D. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci 2005, 25:9096-9101.
20. Calabrese B., Shaked G.M., Tabarean I.V., Braga J., Koo E.H., Halpain S. Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein. Mol Cell Neurosci 2007, 35:183-193.
21. Calabrese B., Wilson M.S., Halpain S. Development and regulation of dendritic spine synapses. Physiology (Bethesda, Md) 2006, 21:38-47.
22. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., Younkin L., Good M.A., Bliss T.V., Hyman B.T., Younkin S.G., Hsiao K.K. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 1999, 2:271-276.
23. Chen G., Chen K.S., Knox J., Inglis J., Bernard A., Martin S.J., Justice A., McConlogue L., Games D., Freedman S.B., Morris R.G. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000, 408:975-979.
24. Chen Q.S., Kagan B.L., Hirakura Y., Xie C.W. Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J Neurosci Res 2000, 60:65-72.
25. Chetelat G., Desgranges B., Landeau B., Mezenge F., Poline J.B., de la Sayette V., Viader F., Eustache F., Baron J.C. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 2008, 131:60-71.
26. Chetelat G., Villemagne V.L., Pike K.E., Ellis K.A., Ames D., Masters C.L., Rowe C.C. Relationship between memory performance and beta-amyloid deposition at different stages of Alzheimer's disease. Neurodegener Dis 2012, 10:141-144.
27. Chicurel M.E., Harris K.M. Three-dimensional analysis of the structure and composition of CA3 branched dendritic spines and their synaptic relationships with mossy fiber boutons in the rat hippocampus. J Comp Neurol 1992, 325:169-182.
28. Chong S.A., Benilova I., Shaban H., De Strooper B., Devijver H., Moechars D., Eberle W., Bartic C., Van Leuven F., Callewaert G. Synaptic dysfunction in hippocampus of transgenic mouse models of Alzheimer's disease: a multi-electrode array study. Neurobiol Dis 2011, 44:284-291.
29. Chow V.W., Mattson M.P., Wong P.C., Gleichmann M. An overview of APP processing enzymes and products. Neuromolecular Med 2009.
30. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser P., St George Hyslop P., Selkoe D.J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 1997, 3:67-72.
31. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005, 8:79-84.
32. Costantini C., Della-Bianca V., Formaggio E., Chiamulera C., Montresor A., Rossi F. The expression of p75 neurotrophin receptor protects against the neurotoxicity of soluble oligomers of beta-amyloid. Exp Cell Res 2005, 311:126-134.
33. Coulson E.J. Does the p75 neurotrophin receptor mediate Abeta-induced toxicity in Alzheimer's disease?. J Neurochem 2006, 98:654-660.
34. Crystal H., Dickson D., Fuld P., Masur D., Scott R., Mehler M., Masdeu J., Kawas C., Aronson M., Wolfson L. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988, 38:1682-1687.
35. De Felice F., Vieira M., Bomfim T., Decker H., Velasco P., Lambert M., Viola K., Zhao W., Ferreira S., Klein W. Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of A{beta} oligomers. Proc Natl Acad Sci USA 2009.
36. De Felice F.G., Velasco P.T., Lambert M.P., Viola K., Fernandez S.J., Ferreira S.T., Klein W.L. Abeta oligomers induce neuronal oxidative stress through an N-methyl-d-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 2007, 282:11590-11601.
37. Dechant G., Barde Y.A. The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. Nat Neurosci 2002, 5:1131-1136.
38. DeKosky S.T., Scheff S.W., Styren S.D. Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration 1996, 5:417-421.
39. Delaere P., Duyckaerts C., Brion J.P., Poulain V., Hauw J.J. Tau, paired helical filaments and amyloid in the neocortex: a morphometric study of 15 cases with graded intellectual status in aging and senile dementia of Alzheimer type. Acta Neuropathol 1989, 77:645-653.
40. Dewachter I., Filipkowski R.K., Priller C., Ris L., Neyton J., Croes S., Terwel D., Gysemans M., Devijver H., Borghgraef P., Godaux E., Kaczmarek L., Herms J., Van Leuven F. Deregulation of NMDA-receptor function and down-stream signaling in APP[V717I] transgenic mice. Neurobiol Aging 2009, 30:241-256.
41. Dickstein D.L., Brautigam H., Stockton S.D., Schmeidler J., Hof P.R. Changes in dendritic complexity and spine morphology in transgenic mice expressing human wild-type tau. Brain Struct Funct 2010, 214:161-179.
42. Dodart J.C., Mathis C., Saura J., Bales K.R., Paul S.M., Ungerer A. Neuroanatomical abnormalities in behaviorally characterized APP(V717F) transgenic mice. Neurobiol Dis 2000, 7:71-85.
43. Dong H., Martin M.V., Chambers S., Csernansky J.G. Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice. J Comp Neurol 2007, 500:311-321.
44. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996, 383:710-713.
45. Eckermann K., Mocanu M.M., Khlistunova I., Biernat J., Nissen A., Hofmann A., Schonig K., Bujard H., Haemisch A., Mandelkow E., Zhou L., Rune G., Mandelkow E.M. The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J Biol Chem 2007, 282:31755-31765.
46. Fiala J.C., Feinberg M., Popov V., Harris K.M. Synaptogenesis via dendritic filopodia in developing hippocampal area CA1. J Neurosci 1998, 18:8900-8911.
47. Fiala J.C., Kirov S.A., Feinberg M.D., Petrak L.J., George P., Goddard C.A., Harris K.M. Timing of neuronal and glial ultrastructure disruption during brain slice preparation and recovery in vitro. J Comp Neurol 2003, 465:90-103.
48. Findeis M.A. The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol Ther 2007, 116:266-286.
49. Fitzjohn S.M., Kuenzi F., Morton R.A., Rosahl T.W., Lewis H., Smith D., Seabrook G.R., Collingridge G.L. A study of long-term potentiation in transgenic mice over-expressing mutant forms of both amyloid precursor protein and presenilin-1. Mol Brain 2010, 3:21.
50. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
51. Gandy S., Simon A.J., Steele J.W., Lublin A.L., Lah J.J., Walker L.C., Levey A.I., Krafft G.A., Levy E., Checler F., Glabe C., Bilker W.B., Abel T., Schmeidler J., Ehrlich M.E. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol 2010, 68:220-230.
52. Gerlai R., Fitch T., Bales K.R., Gitter B.D. Behavioral impairment of APP(V717F) mice in fear conditioning: is it only cognition?. Behav Brain Res 2002, 136:503-509.
53. Giannakopoulos P., Herrmann F.R., Bussiere T., Bouras C., Kovari E., Perl D.P., Morrison J.H., Gold G., Hof P.R. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003, 60:1495-1500.
54. Gonatas N.K., Anderson W., Evangelista I. The contribution of altered synapses in the senile plaque: an electron microscopic study in Alzheimer's dementia. J Neuropathol Exp Neurol 1967, 26:25-39.
55. Gong B., Cao Z., Zheng P., Vitolo O.V., Liu S., Staniszewski A., Moolman D., Zhang H., Shelanski M., Arancio O. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 2006, 126:775-788.
56. Gong B., Vitolo O.V., Trinchese F., Liu S., Shelanski M., Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 2004, 114:1624-1634.
57. Gordon M.N., King D.L., Diamond D.M., Jantzen P.T., Boyett K.V., Hope C.E., Hatcher J.M., DiCarlo G., Gottschall W.P., Morgan D., Arendash G.W. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol Aging 2001, 22:377-385.
58. Gotz J., Barmettler R., Ferrari A., Goedert M., Probst A., Nitsch R.M. In vivo analysis of wild-type and FTDP-17 tau transgenic mice. Ann N Y Acad Sci 2000, 920:126-133.
59. Gotz J., Probst A., Spillantini M.G., Schafer T., Jakes R., Burki K., Goedert M. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J 1995, 14:1304-1313.
60. Gray E.G., Westrum L.E., Burgoyne R.D., Barron J. Synaptic organisation and neuron microtubule distribution. Cell Tissue Res 1982, 226:579-588.
61. Griffin R.J., Moloney A., Kelliher M., Johnston J.A., Ravid R., Dockery P., O'Connor R., O'Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J Neurochem 2005, 93:105-117.
62. Gruart A., Munoz M.D., Delgado-Garcia J.M. Involvement of the CA3-CA1 synapse in the acquisition of associative learning in behaving mice. J Neurosci 2006, 26:1077-1087.
63. Grutzendler J., Helmin K., Tsai J., Gan W.B. Various dendritic abnormalities are associated with fibrillar amyloid deposits in Alzheimer's disease. Ann N Y Acad Sci 2007, 1097:30-39.
64. Gureviciene I., Ikonen S., Gurevicius K., Sarkaki A., van Groen T., Pussinen R., Ylinen A., Tanila H. Normal induction but accelerated decay of LTP in APP+PS1 transgenic mice. Neurobiol Dis 2004, 15:188-195.
65. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998, 279:509-514.
66. Hall A., Nobes C.D. Rho GTPases: molecular switches that control the organization and dynamics of the actin cytoskeleton. Philos Trans R Soc Lond B Biol Sci 2000, 355:965-970.
67. Harris J.A., Devidze N., Halabisky B., Lo I., Thwin M.T., Yu G.Q., Bredesen D.E., Masliah E., Mucke L. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci 2010, 30:372-381.
68. Harris K.M., Kater S.B. Dendritic spines: cellular specializations imparting both stability and flexibility to synaptic function. Annu Rev Neurosci 1994, 17:341-371.
69. Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., Teplow D.B., Selkoe D.J. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999, 19:8876-8884.
70. Hawkins P.T., Eguinoa A., Qiu R.G., Stokoe D., Cooke F.T., Walters R., Wennstr/Hom S., Claesson-Welsh L., Evans T., Symons M. PDGF stimulates an increase in GTP-Rac via activation of phosphoinositide 3-kinase. Curr Biol 1995, 5:393-403.
71. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998, 4:97-100.
72. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
73. Ingelsson M., Fukumoto H., Newell K.L., Growdon J.H., Hedley-Whyte E.T., Frosch M.P., Albert M.S., Hyman B.T., Irizarry M.C. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004, 62:925-931.
74. Ishihara T., Higuchi M., Zhang B., Yoshiyama Y., Hong M., Trojanowski J.Q., Lee V.M. Attenuated neurodegenerative disease phenotype in tau transgenic mouse lacking neurofilaments. J Neurosci 2001, 21:6026-6035.
75. Ishikawa Y., Katoh H., Negishi M. A role of Rnd1 GTPase in dendritic spine formation in hippocampal neurons. J Neurosci 2003, 23:11065-11072.
76. Jacinto E., Loewith R., Schmidt A., Lin S., Rüegg M.A., Hall A., Hall M.N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004, 6:1122-1128.
77. Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., Knopman D.S., Boeve B.F., Klunk W.E., Mathis C.A., Petersen R.C. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131:665-680.
78. Jack C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., Shiung M.M., Gunter J.L., Boeve B.F., Kemp B.J., Weiner M., Petersen R.C. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365.
79. Jacobsen J.S., Wu C.C., Redwine J.M., Comery T.A., Arias R., Bowlby M., Martone R., Morrison J.H., Pangalos M.N., Reinhart P.H., Bloom F.E. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2006, 103:5161-5166.
80. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
81. Jones E.G., Powell T.P. Morphological variations in the dendritic spines of the neocortex. J Cell Sci 1969, 5:509-529.
82. Kawahara M., Kuroda Y. Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: channel formation and disruption of calcium homeostasis. Brain Res Bull 2000, 53:389-397.
83. Kennedy M.B. Signal-processing machines at the postsynaptic density. Science 2000, 290:750-754.
84. Khurana V., Lu Y., Steinhilb M.L., Oldham S., Shulman J.M., Feany M.B. TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr Biol 2006, 16:230-241.
85. Klein W.L. Synaptic targeting by A beta oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease. Alzheimers Dement 2006, 2:43-55.
86. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004, 55:306-319.
87. Knobloch M., Farinelli M., Konietzko U., Nitsch R.M., Mansuy I.M. Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci 2007, 27:7648-7653.
88. Kumar V., Zhang M.-X., Swank M.W., Kunz J., Wu G.-Y. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J Neurosci 2005, 25:11288-11299.
89. La Ferla B., Airoldi C., Zona C., Orsato A., Cardona F., Merlo S., Sironi E., D'Orazio G., Nicotra F. Natural glycoconjugates with antitumor activity. Nat Prod Rep 2010, 28:630-648.
90. Lacor P.N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., Viola K.L., Klein W.L. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007, 27:796-807.
91. Lafay-Chebassier C., Paccalin M., Page G., Barc-Pain S., Perault-Pochat M.C., Gil R., Pradier L., Hugon J. mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease. J Neurochem 2005, 94:215-225.
92. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998, 95:6448-6453.
93. Langstrom N.S., Anderson J.P., Lindroos H.G., Winblad B., Wallace W.C. Alzheimer's disease-associated reduction of polysomal mRNA translation. Brain Res Mol Brain Res 1989, 5:259-269.
94. Lanz T.A., Carter D.B., Merchant K.M. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol Dis 2003, 13:246-253.
95. Lauren J., Gimbel D.A., Nygaard H.B., Gilbert J.W., Strittmatter S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009, 457:1128-1132.
96. Lee, Kuo, Huang, Huang Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation. Neurobiol Aging 2007.
97. Leemhuis J., Mayer U., Barth H., Schmidt G., Meyer D.K. The small GTPase Rac is involved in clustering of hippocampal neurons and fasciculation of their neurites. Naunyn Schmiedebergs Arch Pharmacol 2004, 370:211-222.
98. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
99. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000, 25:402-405.
100. Li X., Alafuzoff I., Soininen H., Winblad B., Pei J.-J. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J 2005, 272:4211-4220.
101. Lombardo J.A., Stern E.A., McLellan M.E., Kajdasz S.T., Hickey G.A., Bacskai B.J., Hyman B.T. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 2003, 23:10879-10883.
102. Lorenzo A., Yuan M., Zhang Z., Paganetti P.A., Sturchler-Pierrat C., Staufenbiel M., Mautino J., Vigo F.S., Sommer B., Yankner B.A. Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. Nat Neurosci 2000, 3:460-464.
103. Lu D.C., Shaked G.M., Masliah E., Bredesen D.E., Koo E.H. Amyloid beta protein toxicity mediated by the formation of amyloid-beta protein precursor complexes. Ann Neurol 2003, 54:781-789.
104. Lu D.C., Soriano S., Bredesen D.E., Koo E.H. Caspase cleavage of the amyloid precursor protein modulates amyloid beta-protein toxicity. J Neurochem 2003, 87:733-741.
105. Magdesian M.H., Carvalho M.M., Mendes F.A., Saraiva L.M., Juliano M.A., Juliano L., Garcia-Abreu J., Ferreira S.T. Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J Biol Chem 2008, 283:9359-9368.
106. Malenka R.C., Bear M.F. LTP and LTD: an embarrassment of riches. Neuron 2004, 44:5-21.
107. Malenka R.C., Nicoll R.A. Long-term potentiation-a decade of progress?. Science 1999, 285:1870-1874.
108. Malm T.M., Iivonen H., Goldsteins G., Keksa-Goldsteine V., Ahtoniemi T., Kanninen K., Salminen A., Auriola S., Van Groen T., Tanila H., Koistinaho J. Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. J Neurosci 2007, 27:3712-3721.
109. Marchetti C., Marie H. Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models?. Rev Neurosci 2011, 22:373-402.
110. Martín D., Salinas M., López-Valdaliso R., Serrano E., Recuero M., Cuadrado A. Effect of the Alzheimer amyloid fragment Abeta (25-35) on Akt/PKB kinase and survival of PC12 cells. J Neurochem 2001, 78:1000-1008.
111. Masliah E., Mallory M., Hansen L., DeTeresa R., Terry R.D. Quantitative synaptic alterations in the human neocortex during normal aging. Neurology 1993, 43:192-197.
112. Masliah E., Terry R. The role of synaptic proteins in the pathogenesis of disorders of the central nervous system. Brain Pathol 1993, 3:77-85.
113. Masliah E., Terry R.D., DeTeresa R.M., Hansen L.A. Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci Lett 1989, 103:234-239.
114. Matsuzaki M., Honkura N., Ellis-Davies G.C.R., Kasai H. Structural basis of long-term potentiation in single dendritic spines. Nature 2004, 429:761-766.
115. Montgomery K.S., Simmons R.K., Edwards G., Nicolle M.M., Gluck M.A., Myers C.E., Bizon J.L. Novel age-dependent learning deficits in a mouse model of Alzheimer's disease: implications for translational research. Neurobiol Aging 2009, 32:1273-1285.
116. Moolman D.L., Vitolo O.V., Vonsattel J.P., Shelanski M.L. Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol 2004, 33:377-387.
117. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
118. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L., Koeppe R.A., Mathis C.A., Weiner M.W., Jagust W.J. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323.
119. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice. Synaptotoxicity without plaque formation. J Neurosci 2000, 20:4050-4058.
120. Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B., Lannfelt L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992, 1:345-347.
121. Murrell J., Farlow M., Ghetti B., Benson M.D. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991, 254:97-99.
122. Nagerl U.V., Eberhorn N., Cambridge S.B., Bonhoeffer T. Bidirectional activity-dependent morphological plasticity in hippocampal neurons. Neuron 2004, 44:759-767.
123. Nakayama A.Y., Harms M.B., Luo L. Small GTPases Rac and Rho in the maintenance of dendritic spines and branches in hippocampal pyramidal neurons. J Neurosci 2000, 20:5329-5338.
124. Newey S.E., Velamoor V., Govek E.-E.E., Van Aelst L. Rho GTPases, dendritic structure, and mental retardation. J Neurobiol 2005, 64:58-74.
125. Nguyen, Galvan, Huang, Banwait, Tang, Bredesen Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664. J Neurochem 2007.
126. Niederöst B., Oertle T., Fritsche J., McKinney R.A., Bandtlow C.E. Nogo-A and myelin-associated glycoprotein mediate neurite growth inhibition by antagonistic regulation of RhoA and Rac1. J Neurosci 2002, 22:10368-10376.
127. Nimmrich V., Ebert U. Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid. Rev Neurosci 2009, 20:1-12.
128. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., Yoo J., Ho K.O., Yu G.Q., Kreitzer A., Finkbeiner S., Noebels J.L., Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
129. Parnass Z., Tashiro A., Yuste R. Analysis of spine morphological plasticity in developing hippocampal pyramidal neurons. Hippocampus 2000, 10:561-568.
130. Pei J.-J., Khatoon S., An W.-L., Nordlinder M., Tanaka T., Braak H., Tsujio I., Takeda M., Alafuzoff I., Winblad B., Cowburn R.F., Grundke-Iqbal I., Iqbal K. Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol 2003, 105:381-392.
131. Peters A., Kaiserman-Abramof I.R. The small pyramidal neuron of the rat cerebral cortex. The perikaryon, dendrites and spines. Am J Anat 1970, 127:321-355.
132. Petratos S., Li Q.-X., George A.J., Hou X., Kerr M.L., Unabia S.E., Hatzinisiriou I., Maksel D., Aguilar M.-I., Small D.H. The -amyloid protein of Alzheimer's disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism. Brain 2008, 131:90-108.
133. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., Mathis C.A., Klunk W.E., Masters C.L., Rowe C.C. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130:2837-2844.
134. Polydoro M., Acker C.M., Duff K., Castillo P.E., Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 2009, 29:10741-10749.
135. Probst A., Gotz J., Wiederhold K.H., Tolnay M., Mistl C., Jaton A.L., Hong M., Ishihara T., Lee V.M., Trojanowski J.Q., Jakes R., Crowther R.A., Spillantini M.G., Burki K., Goedert M. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol 2000, 99:469-481.
136. Purpura D.P. Dendritic differentiation in human cerebral cortex: normal and aberrant developmental patterns. Adv Neurol 1975, 12:91-134.
137. Puzzo D., Arancio O. Fibrillar beta-amyloid impairs the late phase of long term potentiation. Curr Alzheimer Res 2006, 3:179-183.
138. Puzzo D., Privitera L., Fa M., Staniszewski A., Hashimoto G., Aziz F., Sakurai M., Ribe E.M., Troy C.M., Mercken M., Jung S.S., Palmeri A., Arancio O. Endogenous amyloid-beta is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 2011, 69:819-830.
139. Puzzo D., Privitera L., Leznik E., Fa M., Staniszewski A., Palmeri A., Arancio O. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 2008, 28:14537-14545.
140. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N Engl J Med 2010, 362:329-344.
141. Rabinovici G.D., Furst A.J., O'Neil J.P., Racine C.A., Mormino E.C., Baker S.L., Chetty S., Patel P., Pagliaro T.A., Klunk W.E., Mathis C.A., Rosen H.J., Miller B.L., Jagust W.J. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007, 68:1205-1212.
142. Ramon y Cajal S. Estructura de los centros nerviosos de las aves. Rev Trim Histol Norm Pat 1888, 1:1-10.
143. Rocher A.B., Crimins J.L., Amatrudo J.M., Kinson M.S., Todd-Brown M.A., Lewis J., Luebke J.I. Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp Neurol 2009, 223:385-393.
144. Rocher A.B., Kinson M.S., Luebke J.I. Significant structural but not physiological changes in cortical neurons of 12-month-old Tg2576 mice. Neurobiol Dis 2008, 32:309-318.
145. Rodgers E.E., Theibert A.B. Functions of PI 3-kinase in development of the nervous system. Int J Dev Neurosci 2002, 20:187-197.
146. Rohatgi R., Ho H.Y., Kirschner M.W. Mechanism of N-WASP activation by CDC42 and phosphatidylinositol 4, 5-bisphosphate. J Cell Biol 2000, 150:1299-1310.
147. Roher A.E., Ball M.J., Bhave S.V., Wakade A.R. Beta-amyloid from Alzheimer disease brains inhibits sprouting and survival of sympathetic neurons. Biochem Biophys Res Commun 1991, 174:572-579.
148. Roher A.E., Palmer K.C., Capodilupo J., Wakade A.R., Ball M.J. New biochemical insights to unravel the pathogenesis of Alzheimer's lesions. Can J Neurol Sci 1991, 18:408-410.
149. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., Villemagne V.L. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
150. Rozkalne A., Spires-Jones T.L., Stern E.A., Hyman B.T. A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer's disease mouse model. Brain Res 2009, 1280:178-185.
151. Rutten B.P., Van der Kolk N.M., Schafer S., van Zandvoort M.A., Bayer T.A., Steinbusch H.W., Schmitz C. Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. Am J Pathol 2005, 167:161-173.
152. Saganich M.J., Schroeder B.E., Galvan V., Bredesen D.E., Koo E.H., Heinemann S.F. Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. J Neurosci 2006, 26:13428-13436.
153. Sakono M., Zako T. (Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J 2010, 277:1348-1358.
154. Sala C. Molecular regulation of dendritic spine shape and function. Neurosignals 2002, 11:213-223.
155. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., Ashe K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
156. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.-H., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168.
157. Savonenko A., Xu G.M., Melnikova T., Morton J.L., Gonzales V., Wong M.P., Price D.L., Tang F., Markowska A.L., Borchelt D.R. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 2005, 18:602-617.
158. Scheff S.W., Price D.A. Synapse loss in the temporal lobe in Alzheimer's disease. Ann Neurol 1993, 33:190-199.
159. Scheff S.W., Price D.A., Sparks D.L. Quantitative assessment of possible age-related change in synaptic numbers in the human frontal cortex. Neurobiol Aging 2001, 22:355-365.
160. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
161. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008, 192:106-113.
162. Shaked G.M., Kummer M.P., Lu D.C., Galvan V., Bredesen D.E., Koo E.H. Abeta induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597-624. FASEB J 2006, 20:1254-1256.
163. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007, 27:2866-2875.
164. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008, 14:837-842.
165. Shipton O.A., Leitz J.R., Dworzak J., Acton C.E., Tunbridge E.M., Denk F., Dawson H.N., Vitek M.P., Wade-Martins R., Paulsen O., Vargas-Caballero M. Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci 2011, 31:1688-1692.
166. Shrestha B.R., Vitolo O.V., Joshi P., Lordkipanidze T., Shelanski M., Dunaevsky A. Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol Cell Neurosci 2006, 33:274-282.
167. Smith D.L., Pozueta J., Gong B., Arancio O., Shelanski M. Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci USA 2009, 106:16877-16882.
168. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., Nairn A.C., Salter M.W., Lombroso P.J., Gouras G.K., Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005, 8:1051-1058.
169. Spires T.L., Meyer-Luehmann M., Stern E.A., McLean P.J., Skoch J., Nguyen P.T., Bacskai B.J., Hyman B.T. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci 2005, 25:7278-7287.
170. Spires-Jones T.L., Meyer-Luehmann M., Osetek J.D., Jones P.B., Stern E.A., Bacskai B.J., Hyman B.T. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am J Pathol 2007, 171:1304-1311.
171. Spittaels K., Van den Haute C., Van Dorpe J., Bruynseels K., Vandezande K., Laenen I., Geerts H., Mercken M., Sciot R., Van Lommel A., Loos R., Van Leuven F. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol 1999, 155:2153-2165.
172. Stein T.D., Johnson J.A. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci 2002, 22:7380-7388.
173. Swiech L., Perycz M., Malik A., Jaworski J. Role of mTOR in physiology and pathology of the nervous system. Biochim Biophys Acta 2007.
174. Sydow A., Van der Jeugd A., Zheng F., Ahmed T., Balschun D., Petrova O., Drexler D., Zhou L., Rune G., Mandelkow E., D'Hooge R., Alzheimer C., Mandelkow E.M. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci 2011, 31:2511-2525.
175. Tanemura K., Murayama M., Akagi T., Hashikawa T., Tominaga T., Ichikawa M., Yamaguchi H., Takashima A. Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J Neurosci 2002, 22:133-141.
176. Tashiro A., Minden A., Yuste R. Regulation of dendritic spine morphology by the rho family of small GTPases: antagonistic roles of Rac and Rho. Cereb Cortex 2000, 10:927-938.
177. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30:572-580.
178. Thies E., Mandelkow E.M. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci 2007, 27:2896-2907.
179. Townsend, Mehta, Selkoe Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 2007.
180. Trinchese F., Liu S., Battaglia F., Walter S., Mathews P.M., Arancio O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 2004, 55:801-814.
181. Tsai J., Grutzendler J., Duff K., Gan W.B. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 2004, 7:1181-1183.
182. Valincius G., Heinrich F., Budvytyte R., Vanderah D.J., McGillivray D.J., Sokolov Y., Hall J.E., Losche M. Soluble amyloid beta-oligomers affect dielectric membrane properties by bilayer insertion and domain formation: implications for cell toxicity. Biophys J 2008, 95:4845-4861.
183. Villemagne V.L., Pike K.E., Chetelat G., Ellis K.A., Mulligan R.S., Bourgeat P., Ackermann U., Jones G., Szoeke C., Salvado O., Martins R., O'Keefe G., Mathis C.A., Klunk W.E., Ames D., Masters C.L., Rowe C.C. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011, 69:181-192.
184. Vitolo O.V., Sant'Angelo A., Costanzo V., Battaglia F., Arancio O., Shelanski M. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci USA 2002, 99:13217-13221.
185. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
186. Wang H.W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., Viola K.L., Klein W.L., Stine W.B., Krafft G.A., Trommer B.L. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 2002, 924:133-140.
187. Wennerberg K., Forget M.-A., Ellerbroek S.M., Arthur W.T., Burridge K., Settleman J., Der C.J., Hansen S.H. Rnd proteins function as RhoA antagonists by activating p190 RhoGAP. Curr Biol 2003, 13:1106-1115.
188. Wesson D.W., Levy E., Nixon R.A., Wilson D.A. Olfactory dysfunction correlates with amyloid-beta burden in an Alzheimer's disease mouse model. J Neurosci 2010, 30:505-514.
189. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., Carlson G.A., Younkin S.G., Ashe K.H. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2002, 22:1858-1867.
190. White A.R., Zheng H., Galatis D., Maher F., Hesse L., Multhaup G., Beyreuther K., Masters C.L., Cappai R. Survival of cultured neurons from amyloid precursor protein knock-out mice against Alzheimer's amyloid-beta toxicity and oxidative stress. J Neurosci 1998, 18:6207-6217.
191. Whitlock J.R., Heynen A.J., Shuler M.G., Bear M.F. Learning induces long-term potentiation in the hippocampus. Science 2006, 313:1093-1097.
192. Wilcock G.K., Esiri M.M. Plaques, tangles and dementia. A quantitative study. J Neurol Sci 1982, 56:343-356.
193. Wisniewski T., Sigurdsson E.M. Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta 2010, 1802:847-859.
194. Wu C.C., Chawla F., Games D., Rydel R.E., Freedman S., Schenk D., Young W.G., Morrison J.H., Bloom F.E. Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice. Digital morphometric analyses. Proc Natl Acad Sci USA 2004, 101:7141-7146.
195. Yamamoto-Sasaki M., Ozawa H., Saito T., Rosler M., Riederer P. Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res 1999, 824:300-303.
196. Zhang Y., Hong Y., Bounhar Y., Blacker M., Roucou X., Tounekti O., Vereker E., Bowers W.J., Federoff H.J., Goodyer C.G., LeBlanc A. p75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid beta peptide cytotoxicity. J Neurosci 2003, 23:7385-7394.
197. Zhao L., Ma Q.L., Calon F., Harris-White M.E., Yang F., Lim G.P., Morihara T., Ubeda O.J., Ambegaokar S., Hansen J.E., Weisbart R.H., Teter B., Frautschy S.A., Cole G.M. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci 2006, 9:234-242.
198. Zhao W.-Q.Q., De Felice F.G., Fernandez S., Chen H., Lambert M.P., Quon M.J., Krafft G.A., Klein W.L. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 2008, 22:246-260.
199. Zhou Q., Homma K.J., Poo M.M. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron 2004, 44:749-757.